Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Clinics in Georgia

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What Georgia law means for peptide clinics: who may prescribe, whether pharmacies may compound GLP-1 drugs (limited), how to check a clinic, and listings with their verification status.

Georgia at a glance

503A framework
Follows the federal 503A framework
Telehealth prescribing
Regulatory: Telehealth allowed
Asynchronous prescribing
Regulatory: Async not allowed
Compounded GLP-1 access
Regulatory: Compounded GLP-1 limited

Clinics serving Georgia

No verified clinics serving Georgia are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.

Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.

Run a pharmacy, clinic, or telehealth service? Apply for a listing.

Peptide access rules in Georgia

Yes, but Georgia is one of the stricter telehealth states. A Georgia resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from a Georgia-licensed provider, but Georgia Composite Medical Board rule 360-3-.07 generally requires the patient to have been examined in person by a Georgia licensee (or the prescriber to act at that licensee's request) or examined with technology equal or superior to an in-person exam before an initial dangerous drug prescription by telemedicine, and the Board ended its pandemic-era flexibility in 2024. Compounded peptides are available when eligible under federal 503A rules and dispensed by a Georgia pharmacy or a pharmacy holding a Georgia nonresident pharmacy permit (O.C.G.A. 26-4-114.1); nonresident pharmacies that compound must also submit an inspection report. [1] [2] [3] [5] [6] [7] [8] [9] [10] [11] [13]

Compounded GLP-1 access in Georgia

The practical Georgia barrier is the prescription itself. Rule 360-3-.07 lets a Georgia-licensed provider treat by telemedicine only if the provider has personally examined the patient, acts at the request of a Georgia licensee who has, or can examine the patient using technology equal or superior to an in-person exam. The Board said on January 10, 2024 that its rules in general require one in-person exam before an initial prescription for a dangerous drug. [3] [4] [8] [14]

Research use only sellers in Georgia

Only Georgia-licensed pharmacies and permitted nonresident pharmacies may dispense prescription drugs to Georgia patients. "Research use only" peptides sold for human injection are unapproved new drugs under federal law regardless of labeling and are not dispensed by a pharmacist. Georgia law also bars the sale directly: O.C.G.A. 26-3-10 provides that no person shall sell, deliver, offer for sale, hold for sale, or give away any new drug unless an application for it has become effective under section 505 of the federal act (or, for a drug not subject to the federal act, a state application has been filed with the State Board of Pharmacy), with an exemption only for drugs intended solely for investigational use by qualified experts and plainly labeled "For investigational use only." [5] [12] [15]

Georgia notes on specific peptides

  • Semaglutide: Available branded by prescription, but a first telemedicine prescription in Georgia generally requires a prior in-person exam or an exam with technology equal or superior to one under rule 360-3-.07. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025. [3] [14]
  • Tirzepatide: Available branded by prescription under the same Georgia telemedicine exam rule. Compounded tirzepatide is limited to documented patient-specific needs since the 503A grace period ended February 18, 2025, and must come from a Georgia or permitted nonresident pharmacy. [3] [5] [14]

How to check a clinic in Georgia

  1. Confirm the prescribing clinician's license with the Georgia medical or nursing board.
  2. Ask which pharmacy compounds or dispenses the peptide and check it in the Georgia State Board of Pharmacy license lookup. [1] [5] [6] [11] [13]
  3. Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
  4. Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Georgia. [5] [12] [15]

Common questions in Georgia

Do I need an in-person visit to get a GLP-1 prescription by telehealth in Georgia?

Usually, or an exam using technology that is equal or superior to one. Georgia Composite Medical Board rule 360-3-.07 allows telemedicine prescribing when the provider has examined you in person, is acting at the request of a Georgia clinician who has, or can examine you with technology equal or superior to an in-person exam, and the Board has said its rules in general require one in-person exam before an initial dangerous drug prescription. No rule names online questionnaires, but a questionnaire alone does not meet that exam requirement. [3] [7] [8]

All peptide legal questions for Georgia

Sources

  1. [1]Georgia State Board of Pharmacy
  2. [2]Georgia Composite Medical Board
  3. [3]Georgia Composite Medical Board rule 360-3-.07, Practice through electronic or other such means (chapter 360-3)
  4. [4]Georgia Composite Medical Board: Board updates position on telehealth prescribing (December 7, 2023)
  5. [5]O.C.G.A. 26-4-114.1, Nonresident pharmacy permits
  6. [6]Georgia Board of Pharmacy rule 480-6-.02, Nonresident pharmacy permit
  7. [7]Georgia Composite Medical Board rule 360-3-.02, Unprofessional conduct defined (paragraph (6), treatment by electronic means; amended effective August 27, 2024), accessed 2026-09-22
  8. [8]Georgia Composite Medical Board: Board extends tele-prescribing flexibility until May 1 (January 10, 2024), accessed 2026-09-22
  9. [9]O.C.G.A. 16-13-71, Dangerous drug (definition), accessed 2026-09-22
  10. [10]O.C.G.A. 33-24-56.4, Georgia Telehealth Act (definitions; referenced in Board rule 360-3-.02(5); Justia 2025 edition), accessed 2026-09-30